24/09/2020 - 14:48

Netherlands COVID-19 researchers to test PharmAust drugs

24/09/2020 - 14:48

Bookmark

Save articles for future reference.

ASX-listed clinical-stage oncology group, PharmAust, has taken the next significant step towards establishing whether its cancer fighting drug, Monepantel, can also inhibit COVID-19. The Perth-based company has struck an agreement with an internationally renowned biomedical research university in the Netherlands that will examine the suitability of Monepantel and Monepantel Sulfone for the all-important preclinical ex-vivo stage of testing that precedes the critical clinical trials.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options